A phase 1 study of patients with advanced PD-1 positive GC has shown that pembrolizumab had good antitumor activity and controlled toxicity, which needs further verification in phase 2 and 3 trials (Muro et al., 2016). The gene discussed is PDCD1; the disease is gastric cancer.